References
- AutierPBoniolMLa VecchiaCVattenLGavinAHéryCHeanueMDisparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality databaseBMJ2010341c362020702548
- BerryDACroninKAPlevritisSKCancer Intervention and Surveillance Modeling Network (CISNET) CollaboratorsEffect of screening and adjuvant therapy on mortality from breast cancerN Engl J Med2005353171784179216251534
- CardosoFSpenceDMertzSGlobal analysis of advanced/metastatic breast cancer: decade report (2005–2015)Breast20183913113829679849
- HowladerNNooneAMKrapchoM homepage on the InternetSEER Cancer Statistics Review, 1975–2013Bethesda, MDNational Cancer Institute Available from: http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to SEER web site, April 2016
- UfenMPKöhneCHWischneswkyMMetastatic breast cancer: are we treating the same patients as in the past?Ann Oncol20142519510024276026
- PartridgeAHRumbleRBCareyLAChemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol201432293307332925185096
- Al-MahmoodSSapiezynskiJGarbuzenkoOBMinkoTMetastatic and triple-negative breast cancer: challenges and treatment optionsDrug Deliv Transl Res2018851483150729978332
- BianchiniGBalkoJMMayerIASandersMEGianniLTriple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseNat Rev Clin Oncol2016131167469027184417
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)PetoRDaviesCComparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsLancet2012379981443244422152853
- CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
- CareyLADeesECSawyerLThe triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesClin Cancer Res20071382329233417438091
- DecatrisMPSundarSO’ByrneKJPlatinum-based chemotherapy in metastatic breast cancer: current statusCancer Treat Rev2004301538114766126
- WangXWangXGuoZFunctionalization of platinum complexes for biomedical applicationsAcc Chem Res20154892622263126247558
- DewiSLarsenSSrimuninnimitVBenzene-poly-carboxylic acid complex with cis-diammineplatinum (II) dichloride in the treatment of stage IV breast cancer patientsOpen Breast Cancer J20135715
- FaresFAzzamNFaresBLarsenSLindkaer-JensenSBenzene-poly-carboxylic acid complex, a novel anti-cancer agent induces apoptosis in human breast cancer cellsPLoS One201492e8515624523856
- LarsenSButthongkomvongKManikhasABP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phaseBreast Cancer (Dove Med Press)2014617918925473312
- CarlsenKHKramerJFagertunHELarsenSLoratadine and terfena-dine in perennial allergic rhinitis. Treatment of nonresponders to the one drug with the other drugAllergy19934864314368238798
- PocockSJClinical Trial; A Practical ApproachHoboken (NJ)John Wiley & Sons1989
- RazaliNWahYBPower comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling testsJ Stat Model Anal2011212133
- ThomopoulosNTStatistical Distributions; Applications and Parametric Estimation4th edCham, SwitzerlandSpringer International Publishing2017
- SchottJRMatrix Analysis for StatisticsHoboken (NJ)John Wiley & Sons2017
- AltmanDGPractical Statistic for Medical Research1st edLondonChapman & Hall1991
- AgrestiACategorical Data Analysis2nd edHoboken (NJ)John Wiley & Sons2002
- National Research CouncilThe Prevention and Treatment of Missing Data in Clinical TrialsWashington (DC)National Academy Press2010110112
- ShaoJZhaonhBLast observation carry-forward and last observation analysisStat Med2013221524292441
- TabachnickBGFidellLSUsing Multivariate Statistics5th edBostonPearson Education Inc2007
- EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
- RosenbergBVancampLTroskoJEMansourVHPlatinum compounds: a new class of potent antitumour agentsNature196922251913853865782119
- RozencweigMNicaiseCBeerMPhase I study of carboplatin given on a five-day intravenous scheduleJ Clin Oncol19831106216266366128
- GalluzziLMarsiliSVitaleIVitamin B6 metabolism influences the intracellular accumulation of cisplatinCell Cycle201312341742123287530
- MarracheSPathakRKDharSDetouring of cisplatin to access mitochondrial genome for overcoming resistanceProc Natl Acad Sci U S A201411129104441044925002500
- AnisimovVNLarsenSLofbergSBalduevaIAResults and prospects of development of new polyphenolic drugs for cancer patientsOncotarget2017859100951100956
- KristiansenVMDewiSHorsbergTETolerability and pharmacokinetic profile of a novel benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in dogs with malignant mammary tumoursVet Comp Oncol201715111813225764447
- CorbettTValerioteFLorussoPIn vivo methods for screening and preclinical testing: use of rodents solid tumors for drug discoveryTei-cherBAAnticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and ApprovalNew YorkSpringer201375101
- GuldbergPFangJFKirkinADzhandzhougazianKImmunological Study of BP-C1 and the Related Compounds. Cancer Genomic LaboratoryCopenhagenInstitute of Cancer Biology, Danish Cancer Society2011
- Lindkær-JensenSLarsenSHabib-Lindkær-JensenNFagertunHEPositive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substanceDrug Des Devel Ther2015914811490